



RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

PATENT APPLICATION No. 09/705,286
DOCKET NO. T8341.NP

1615 6P/1615

0470

DAE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Weihong Xiong, et al.
SERIAL NO.: 09/705,286
FILED: 11/02/2000
FOR: TRANSDERMAL
ADMINISTRATION OF HUPERZINE
ART UNIT: 1615
EXAMINER:
DOCKET NO.: T8341.NP

CERTIFICATE OF DEPOSIT
UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, under 37 C.F.R. § 1.8 on the date indicated below and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

V. Montague

6-28-02

Date of Deposit

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). Applicant respectfully submits that this Information Disclosure Statement is filed pursuant to:

X 37 C.F.R. § 1.97 (b)(1) or (3), within three months of the filing date of the application, or before a first office action on the merits, whichever occurs last;

COPY OF PAPERS
ORIGINALLY FILED



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

TECH CENTER 1600/2900

RECEIVED

_____ 37 C.F.R. § 1.97 (c), after a first office action on the merits, but before a Final Office Action or a Notice of Allowance, whichever occurs first, and is accompanied by either 1) a statement in accordance with 37 C.F.R. § 1.97(e), or 2) the fee set forth in § 1.17(p); or

_____ 37 C.F.R. § 1.97 (d), after a Final Office Action or Notice of Allowance, whichever occurs first, but on or before payment of the issue fee, and is accompanied by both 1) a statement in accordance with 37 C.F.R. § 1.97(e), and 2) the fee set forth in § 1.17(p).

While no representation is made that any of these references may be "prior art" within the meaning of that term in accordance with 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that the references listed, together with any other references which may have been previously submitted or listed, are the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. §§ 1.97 and 1.98, a copy of each listed reference (or relevant portion thereof) which was not previously submitted to, or cited by, the Patent Office is also enclosed.

Assistant Commissioner for Patents

COPY OF PAPERS
ORIGINALLY FILED

Page -3-

RECEIVED
JUL 23 2002
TECH CENTER 18012900

For all listed references that are not either in the English language, or accompanied by a translation into English, a concise explanation of relevance as required under 37 C.F.R. §

1.98(a)(3) is enclosed attached to each.

Please charge any additional fees or credit any overpayment to Deposit Account No. 20-0100.

DATED this 28th day of June, 2002.

Respectfully submitted,


M. Wayne Western

M. Wayne Western
Attorney for Applicant
Registration No. 22,788

THORPE NORTH & WESTERN, L.L.P.
Customer No. 20,452
P.O. Box 1219
Sandy, Utah 84091-1219
Telephone (801) 566-6633

MWW/DWO/vm

H:\FILES\T8000\T8341\T8341NP\suppids-2.wpd



JUN-04-2002 18:24

COPY OF PAPERS
ORIGINALLY FILED

901 983 0342 P.02/03

PATENT APPLICATION
DOCKET NO. T8341.NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Xiong et al.	CERTIFICATE OF DEPOSIT UNDER 37 C.F.R. § 1.8 I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, under 37 C.F.R. § 1.8 on the date indicated below and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231. <i>V. Montague</i> Secretary <i>6-28-02</i> Date of Deposit
SERIAL NO.:	09/705,286	
FILED:	November 2, 2000	
FOR:	TRANSDERMAL ADMINISTRATION OF HUPERZINE	
ART UNIT:		
EXAMINER:		
DOCKET NO.:	T8341.NP	

STATEMENT OF RELEVANCE UNDER 37 C.F.R. § 1.98(a)(3)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please find, pursuant to 37 C.F.R. § 1.98(a)(3), a concise Statement of Relevance for the publication listed below.



RECEIVED

801 983 0342 P.03/03

JUL 11 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

JUL 23 2002

RECEIVED


CN 1.1.111.987A

This Chinese patent is relevant to the present patent application in that it discloses transdermal huperzine sticker for the treatment of Alzheimer's disease. Specifically, the transdermal formulation requires Azone or an Azone mixture as a penetration enhancer to be contained with huperzine in an adhesive polymer layer. The adhesive layer contains 0.1% to 8% w/w of huperzine, and requires 15% to 75%w/w of Azone enhancer. The transdermal huperzine sticker is capable of achieving a transdermal delivery rate in the range of 200-400 ug/cm²/24hr, depending on the specific formulation parameters selected.

The above statements are believed to fully comply with the requirements of 37C.F.R. §.98(a)(3). The Examiner is invited to contact the applicant in the event that there is any deficiency found therein.

DATED this 4th day of June, 2002.

Respectfully submitted,



WEIHONG XIONG

COPY OF PAPERS
ORIGINALLY FILED

Page 2 of 2

TOTAL P.03

TOTAL P.03